Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

PURPOSE: Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) –targeted drugs in patients with non–small-cell lung cancer (NSCLC). We investigated whether dual inhibition of MET/EGFR results in clinical...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Spigel, David R., Ervin, Thomas J., Ramlau, Rodryg A., Daniel, Davey B., Goldschmidt, Jerome H., Blumenschein, George R., Krzakowski, Maciej J., Robinet, Gilles, Godbert, Benoit, Barlesi, Fabrice, Govindan, Ramaswamy, Patel, Taral, Orlov, Sergey V., Wertheim, Michael S., Yu, Wei, Zha, Jiping, Yauch, Robert L., Patel, Premal H., Phan, See-Chun, Peterson, Amy C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878106/
https://ncbi.nlm.nih.gov/pubmed/24101053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.4189
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados